|1.08||-0.0300||-2.70%||Vol 660.51K||1Y Perf -31.96%|
|Apr 20th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||7.00||Analyst Rating||Strong Buy 1.00|
|Potential %||548.15||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Market Cap||61.49M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||2.53||Earnings Date||12th May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||12th May 2021|
|Estimated EPS Next Report||-0.20|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||924.79K|
|Avg. Monthly Volume||721.70K|
|Avg. Quarterly Volume||2.12M|
Allena Pharmaceuticals Inc. (NASDAQ: ALNA) stock closed at 1.08 per share at the end of the most recent trading day (a -2.7% change compared to the prior day closing price) with a volume of 664.24K shares and market capitalization of 61.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. Allena Pharmaceuticals Inc. CEO is Louis Brenner.
The one-year performance of Allena Pharmaceuticals Inc. stock is -31.96%, while year-to-date (YTD) performance is -15.63%. ALNA stock has a five-year performance of %. Its 52-week range is between 1.02 and 3.39, which gives ALNA stock a 52-week price range ratio of 2.53%
Allena Pharmaceuticals Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 2.82, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -86.36%, a ROC of -106.05% and a ROE of -159.08%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Allena Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Allena Pharmaceuticals Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Allena Pharmaceuticals Inc. is Strong Buy (1), with a target price of $7, which is +548.15% compared to the current price. The earnings rating for Allena Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Allena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Allena Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 26.36, ATR14 : 0.15, CCI20 : -150.55, Chaikin Money Flow : -0.11, MACD : -0.17, Money Flow Index : 24.11, ROC : -20.14, RSI : 32.52, STOCH (14,3) : 15.38, STOCH RSI : 0.00, UO : 46.03, Williams %R : -84.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Allena Pharmaceuticals Inc. in the last 12-months were: Edward Wholihan (Option Excercise at a value of $0), Edward Wholihan (Sold 68 550 shares of value $93 228 ), Louis Brenner (Option Excercise at a value of $0), Louis Brenner (Sold 103 116 shares of value $140 238 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.